Fangzhou rolls out Novo Nordisk’s once‑weekly basal insulin/GLP-1 therapy in China, creating a new convenience‑driven option in the diabetes market
Executive summary: Fangzhou launched Kyinsu®, the world’s first once‑weekly basal insulin/GLP-1 receptor agonist combination therapy, on its Internet hospital platform in China. The launch introduces a novel dosing convenience that could capture share from daily basal insulin and injectable GLP-1 therapies in the world’s largest diabetes market.
Who is involved: Fangzhou (China‑based internet hospital operator), Novo Nordisk (developer of the insulin/GLP-1 molecule), Chinese patients and regulators.
Likely next: Novo Nordisk and Fangzhou will seek NRDL reimbursement in late 2026 and expand distribution to tier‑2/3 hospitals through 2027, while initiating a Phase IV outcomes study.
Fangzhou’s rollout of Novo Nordisk’s once‑weekly basal insulin/GLP‑1 combination in China introduces a dosing‑frequency advantage to the country’s diabetes care landscape. The therapy, which pairs an insulin degludec analog with semaglutide, is being made available through Fangzhou’s online hospital network, marking the first time Chinese patients can access a single‑injection weekly regimen that combines basal insulin with a GLP‑1 receptor agonist. This launch follows Novo Nordisk’s broader strategy of extending its once‑weekly injectable portfolio beyond the GLP‑1‑only semaglutide products already present in the market. The commercial impact of the product will largely depend on how quickly it secures inclusion in national and provincial reimbursement lists, the price point set relative to existing basal insulin and GLP‑1 therapies, and the willingness of physicians to prescribe a combined regimen versus separate agents. If reimbursement is attained and pricing aligns with payer expectations, the therapy could capture share from both basal insulin and GLP‑1 markets, especially among patients seeking fewer injections. In the near term, Fangzhou may expand the offering to additional tiers of its digital health platform, while Novo Nordisk monitors real‑world usage data to inform any future label expansions or formulation tweaks.
Timeline
- — Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China (GlobeNewswire)
- — Wegovy Pill in Europe - Novo Nordisk Expands Franchise With First European Approval for Oral Weight Loss Drug (Yahoo Finance)
Analysis — what this means
Likely next events
- Novo Nordisk expects to submit Kyinsu® for inclusion in China’s National Reimbursement Drug List (NRDL) by Q4 2026.
- Fangzhou plans to make Kyinsu® available in 150 tier‑2 and tier‑3 hospitals by the end of 2027.
- A Phase IV real‑world safety study of Kyinsu® involving 5,000 Chinese patients is scheduled to report top‑line results in H1 2027.
Sectors affected
- diabetes care
- obesity therapeutics
- Chinese hospital‑based pharmaceutical distribution
Regulatory implications
- China NMPA requires a post‑marketing pharmacovigilance report within 12 months of Kyinsu® launch.
- The product is classified as a Class III biologic, triggering a 30‑day review clock for any label extension or dosage change.
- Any future formulation adjustments must be submitted via a supplemental NDA to the NMPA.
Historical parallels
- Eli Lilly’s basal insulin/GLP‑1 combo iGlarLixi received EMA approval in March 2022.
- Sanofi’s investigational basal insulin/GLP‑1 combination (Lantus®+lixisenatide) completed Phase III testing in 2021.
- Novo Nordisk’s once‑weekly semaglutide (Wegovy®) gained US FDA approval in June 2021.
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped